These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 17394943

  • 1. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy.
    Palma D, Tyldesley S, Blood P, Liu M, Morris J, Pickles T, Prostate Cohort Outcomes Initiative.
    Int J Radiat Oncol Biol Phys; 2007 Apr 01; 67(5):1425-9. PubMed ID: 17394943
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
    Lee AK, Levy LB, Cheung R, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):456-62. PubMed ID: 15927415
    [Abstract] [Full Text] [Related]

  • 4. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
    Aizer AA, Yu JB, McKeon AM, Decker RH, Colberg JW, Peschel RE.
    Int J Radiat Oncol Biol Phys; 2009 Dec 01; 75(5):1344-9. PubMed ID: 19464821
    [Abstract] [Full Text] [Related]

  • 5. Obesity as a predictor of biochemical recurrence and survival after radiation therapy for prostate cancer.
    Palma D, Pickles T, Tyldesley S, Prostate Cohort Outcomes Initiative.
    BJU Int; 2007 Aug 01; 100(2):315-9. PubMed ID: 17617138
    [Abstract] [Full Text] [Related]

  • 6. Radiotherapy for men with isolated increase in serum prostate specific antigen after radical prostatectomy.
    Macdonald OK, Schild SE, Vora SA, Andrews PE, Ferrigni RG, Novicki DE, Swanson SK, Wong WW.
    J Urol; 2003 Nov 01; 170(5):1833-7. PubMed ID: 14532786
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Ludgate CM, Bishop DC, Pai H, Eldridge B, Lim J, Berthelet E, Blood P, Piercy GB, Steinhoff G.
    Int J Radiat Oncol Biol Phys; 2005 Aug 01; 62(5):1309-15. PubMed ID: 16029786
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy.
    Sengupta S, Myers RP, Slezak JM, Bergstralh EJ, Zincke H, Blute ML.
    J Urol; 2005 Dec 01; 174(6):2191-6. PubMed ID: 16280762
    [Abstract] [Full Text] [Related]

  • 13. Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH.
    King CR, Freedland SJ, Terris MK, Aronson WJ, Kane CJ, Amling CL, Presti JC.
    Urology; 2007 Apr 01; 69(4):732-7. PubMed ID: 17445660
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg D, Pollack A.
    Am J Clin Oncol; 2006 Oct 01; 29(5):458-62. PubMed ID: 17023779
    [Abstract] [Full Text] [Related]

  • 17. [Salvage radiotherapy for patients with PSA relapse after radical prostatectomy: comparisons among ASTRO and Phoenix biochemical failure definitions].
    Quero L, Mongiat-Artus P, Ravery V, Hennequin V, Maylin C, Desgrandchamps F, Hennequin C.
    Cancer Radiother; 2009 Jul 01; 13(4):267-75. PubMed ID: 19446487
    [Abstract] [Full Text] [Related]

  • 18. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer.
    Potters L, Morgenstern C, Calugaru E, Fearn P, Jassal A, Presser J, Mullen E.
    J Urol; 2005 May 01; 173(5):1562-6. PubMed ID: 15821486
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.